Mucosal immune responses to microbiota in the development of autoimmune disease

Rheumatic Disease Clinics of North America

Volumn 40, Issue 4, 2014, Pages 711-725

  Kuhn, Kristine A ^a   Pedraza, Isabel ^b   Demoruelle, M Kristen ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Autoimmune disease; Microbiota; Mucosal immunity; Pathogenesis

Indexed keywords

ANTIGEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BYSTANDER EFFECT; EXPOSURE; HUMAN; IMMUNOREACTIVITY; LUPUS VULGARIS; MACROPHAGE ACTIVATION; MICROFLORA; MICROORGANISM; MOLECULAR MIMICRY; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SPONDYLARTHRITIS; T LYMPHOCYTE; IMMUNOLOGY;

AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, MUCOSAL; MICROBIOTA; MOLECULAR MIMICRY;

EID: 84908069135     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.07.013     Document Type: Review

References (94)

1. Backhed F., Ley R.E., Sonnenburg J.L., et al. Host-bacterial mutualism in the human intestine. Science 2005, 307:1915-1920.
2. Shafquat A., Joice R., Simmons S.L., et al. Functional and phylogenetic assembly of microbial communities in the human microbiome. Trends Microbiol 2014, 22:261-266.
3. Ivanov I.I., Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe 2012, 12:496-508.
4. Gallo R.L., Hooper L.V. Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol 2012, 12:503-516.
5. Cheroutre H. IELs: enforcing law and order in the court of the intestinal epithelium. Immunol Rev 2005, 206:114-131.
6. Erle D.J., Pabst R. Intraepithelial lymphocytes in the lung: a neglected lymphocyte population. Am J Respir Cell Mol Biol 2000, 22:398-400.
7. Cheroutre H., Lambolez F., Mucida D. The light and dark sides of intestinal intraepithelial lymphocytes. Nat Rev Immunol 2011, 11:445-456.
8. Murphy K., Travers P., Walport M., et al. Janeway's immunobiology 2012, Garland Science, New York. 8th edition.
9. Macpherson A.J., Slack E., Geuking M.B., et al. The mucosal firewalls against commensal intestinal microbes. Semin Immunopathol 2009, 31:145-149.
10. Zheng N.Y., Wilson K., Wang X., et al. Human immunoglobulin selection associated with class switch and possible tolerogenic origins for C delta class-switched B cells. JClin Invest 2004, 113:1188-1201.
11. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273.
12. Foo S.Y., Phipps S. Regulation of inducible BALT formation and contribution to immunity and pathology. Mucosal Immunol 2010, 3:537-544.
13. Bauer H., Horowitz R.E., Levenson S.M., et al. The response of the lymphatic tissue to the microbial flora. Studies on germfree mice. Am J Pathol 1963, 42:471-483.
14. Clarke T.B., Davis K.M., Lysenko E.S., et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010, 16:228-231.
15. Ganal S.C., Sanos S.L., Kallfass C., et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 2012, 37:171-186.
16. Pereira P., Forni L., Larsson E.L., et al. Autonomous activation of B and T cells in antigen-free mice. Eur J Immunol 1986, 16:685-688.
17. Hooijkaas H., Benner R., Pleasants J.R., et al. Isotypes and specificities of immunoglobulins produced by germ-free mice fed chemically defined ultrafiltered "antigen-free" diet. Eur J Immunol 1984, 14:1127-1130.
18. Atarashi K., Tanoue T., Oshima K., et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500:232-236.
19. Atarashi K., Tanoue T., Shima T., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011, 331:337-341.
20. Ivanov I.I., Atarashi K., Manel N., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
21. Mazmanian S.K., Liu C.H., Tzianabos A.O., et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005, 122:107-118.
22. Mazmanian S.K., Round J.L., Kasper D.L. Amicrobial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453:620-625.
23. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
24. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. NEngl J Med 2003, 349:1526-1533.
25. Demoruelle M.K., Parish M.C., Derber L.A., et al. Performance of anti-cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum 2013, 65:2243-2252.
26. Deane K.D., El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol 2014, 10:212-228.
27. Olsen N.J., Karp D.R. Autoantibodies and SLE-the threshold for disease. Nat Rev Rheumatol 2014, 10:181-186.
28. Weisburg W.G., Barns S.M., Pelletier D.A., et al. 16S ribosomal DNA amplification for phylogenetic study. JBacteriol 1991, 173:697-703.
29. Preheim S.P., Perrotta A.R., Friedman J., et al. Computational methods for high-throughput comparative analyses of natural microbial communities. Meth Enzymol 2013, 531:353-370.
30. Goldstein I., Rebeyrotte P., Parlebas J., et al. Isolation from heart valves of glycopeptides which share immunological properties with Streptococcus haemolyticus group A polysaccharides. Nature 1968, 219:866-868.
31. Bryant P.A., Smyth G.K., Gooding T., et al. Susceptibility to acute rheumatic fever based on differential expression of genes involved in cytotoxicity, chemotaxis, and apoptosis. Infect Immun 2014, 82:753-761.
32. McGraw W.T., Potempa J., Farley D., et al. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun 1999, 67:3248-3256.
33. Wegner N., Wait R., Sroka A., et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis and Rheum 2010, 62:2662-2672.
34. Hill J.A., Southwood S., Sette A., et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. JImmunol 2003, 171:538-541.
35. Vong L., Lorentz R.J., Assa A., et al. Probiotic Lactobacillus rhamnosus inhibits the formation of neutrophil extracellular traps. JImmunol 2014, 192:1870-1877.
36. Tadema H., Abdulahad W.H., Lepse N., et al. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology 2011, 50:689-696.
37. Giordani L., Sanchez M., Libri I., et al. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production. JLeukoc Biol 2009, 86:261-271.
38. Kato A., Hulse K.E., Tan B.K., et al. B-lymphocyte lineage cells and the respiratory system. JAllergy Clin Immunol 2013, 131:933-957. [quiz: 58].
39. Schiotz P.O., Egeskjold E.M., Hoiby N., et al. Autoantibodies in serum and sputum from patients with cystic fibrosis. Acta pathologica et microbiologica Scandinavica Section C. Immunology 1979, 87:319-324.
40. Willis V.C., Demoruelle M.K., Derber L.A., et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis and Rheum 2013, 65:2545-2554.
41. Svartz N. The primary cause of rheumatoid arthritis is an infection-the infectious agent exists in milk. Acta Med Scand 1972, 192:231-239.
42. Murray G.R. Discussion on focal sepsis as a factor in disease. Proc R Soc Med 1926, 19:26.
43. Ramirez A.S., Rosas A., Hernandez-Beriain J.A., et al. Relationship between rheumatoid arthritis and Mycoplasma pneumoniae: a case-control study. Rheumatology (Oxford) 2005, 44:912-914.
44. Newkirk M.M., Goldbach-Mansky R., Senior B.W., et al. Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:1433-1441.
45. Rashid T., Ebringer A. Rheumatoid arthritis is linked to Proteus-the evidence. Clin Rheumatol 2007, 26:1036-1043.
46. Silman A.J., Pearson J.E. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002, 4(Suppl 3):S265-S272.
47. Aoki S., Yoshikawa K., Yokoyama T., et al. Role of enteric bacteria in the pathogenesis of rheumatoid arthritis: evidence for antibodies to enterobacterial common antigens in rheumatoid sera and synovial fluids. Ann Rheum Dis 1996, 55:363-369.
48. Ebringer A., Wilson C., Tiwana H. Is rheumatoid arthritis a form of reactive arthritis?. JRheumatol 2000, 27:559-563.
49. Rashid T., Darlington G., Kjeldsen-Kragh J., et al. Proteus IgG antibodies and C-reactive protein in English, Norwegian and Spanish patients with rheumatoid arthritis. Clin Rheumatol 1999, 18:190-195.
50. Roudier J., Petersen J., Rhodes G.H., et al. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc Natl Acad Sci USA 1989, 86:5104-5108.
51. Albani S., Keystone E.C., Nelson J.L., et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med 1995, 1:448-452.
52. Alspaugh M.A., Henle G., Lennette E.T., et al. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. JClin Invest 1981, 67:1134-1140.
53. Eerola E., Mottonen T., Hannonen P., et al. Intestinal flora in early rheumatoid arthritis. Br J Rheumatol 1994, 33:1030-1038.
54. Scher J.U., Sczesnak A., Longman R.S., et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife (Cambridge) 2013, 2:e01202.
55. Liu X., Zou Q., Zeng B., et al. Analysis of fecal lactobacillus community structure in patients with early rheumatoid arthritis. Curr Microbiol 2013, 67:170-176.
56. Vaahtovuo J., Munukka E., Korkeamaki M., et al. Fecal microbiota in early rheumatoid arthritis. JRheumatol 2008, 35:1500-1505.
57. Mikuls T.R., Payne J.B., Yu F., et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol 2014, 66:1090-1100.
58. Lundberg K., Kinloch A., Fisher B.A., et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008, 58:3009-3019.
59. Mikuls T.R., Thiele G.M., Deane K.D., et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis and Rheum 2012, 64:3522-3530.
60. de Smit M., van de Stadt L.A., Janssen K.M., et al. Antibodies against Porphyromonas gingivalis in seropositive arthralgia patients do not predict development of rheumatoid arthritis. Ann Rheum Dis 2014, 73:1277-1279.
61. Scher J.U., Ubeda C., Equinda M., et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis and Rheum 2012, 64:3083-3094.
62. Demoruelle M.K., Weisman M.H., Simonian P.L., et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity?. Arthritis Rheum 2012, 64:1756-1761.
63. Fischer A., Solomon J.J., du Bois R.M., et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012, 106:1040-1047.
64. Klareskog L., Stolt P., Lundberg K., et al. Anew model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38-46.
65. Abrahamsson T.R., Jakobsson H.E., Andersson A.F., et al. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy 2014, 44(6):842-850.
66. Zakharkina T., Heinzel E., Koczulla R.A., et al. Analysis of the airway microbiota of healthy individuals and patients with chronic obstructive pulmonary disease by T-RFLP and clone sequencing. PLoS One 2013, 8:e68302.
67. Haier J., Nasralla M., Franco A.R., et al. Detection of mycoplasmal infections in blood of patients with rheumatoid arthritis. Rheumatology (Oxford) 1999, 38:504-509.
68. van Eden W. Heat-shock proteins as immunogenic bacterial antigens with the potential to induce and regulate autoimmune arthritis. Immunol Rev 1991, 121:5-28.
69. Harlow L., Rosas I.O., Gochuico B.R., et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis and Rheum 2013, 65:869-879.
70. Keat A. Reiter's syndrome and reactive arthritis in perspective. NEngl J Med 1983, 309:1606-1615.
71. Granfors K., Jalkanen S., von Essen R., et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. NEngl J Med 1989, 320:216-221.
72. Granfors K., Jalkanen S., Lindberg A.A., et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet 1990, 335:685-688.
73. Nanagara R., Li F., Beutler A., et al. Alteration of Chlamydia trachomatis biologic behavior in synovial membranes. Suppression of surface antigen production in reactive arthritis and Reiter's syndrome. Arthritis Rheum 1995, 38:1410-1417.
74. Gerard H.C., Branigan P.J., Schumacher H.R., et al. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. JRheumatol 1998, 25:734-742.
75. Kuon W., Holzhutter H.G., Appel H., et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. JImmunol 2001, 167:4738-4746.
76. Ugrinovic S., Mertz A., Wu P., et al. Asingle nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. JImmunol 1997, 159:5715-5723.
77. Rashid T., Ebringer A. Ankylosing spondylitis is linked to Klebsiella-the evidence. Clin Rheumatol 2007, 26:858-864.
78. Stebbings S., Munro K., Simon M.A., et al. Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatology 2002, 41:1395-1401.
79. Stoll M.L., Kumar R., Morrow C., et al. A175: dysbiosis of the enteric microbiota in pediatric spondyloarthritis. Arthritis Rheumatol 2014, 66(Suppl 11):S228-S229.
80. Morgan X.C., Tickle T.L., Sokol H., et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012, 13:R79.
81. Miquel S., Martin R., Rossi O., et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 2013, 16:255-261.
82. James J.A., Kaufman K.M., Farris A.D., et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. JClin Invest 1997, 100:3019-3026.
83. Pavlovic M., Kats A., Cavallo M., et al. Clinical and molecular evidence for association of SLE with parvovirus B19. Lupus 2010, 19:783-792.
84. Moon U.Y., Park S.J., Oh S.T., et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 2004, 6:R295-R302.
85. Nawata M., Seta N., Yamada M., et al. Possible triggering effect of cytomegalovirus infection on systemic lupus erythematosus. Scand J Rheumatol 2001, 30:360-362.
86. Sutkowski N., Conrad B., Thorley-Lawson D.A., et al. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001, 15:579-589.
87. Ohyama Y., Carroll V.A., Deshmukh U., et al. Severe focal sialadenitis and dacryoadenitis in NZM2328 mice induced by MCMV: a novel model for human Sjogren's syndrome. JImmunol 2006, 177:7391-7397.
88. Shattles W.G., Brookes S.M., Venables P.J., et al. Expression of antigen reactive with a monoclonal antibody to HTLV-1 P19 in salivary glands in Sjogren's syndrome. Clin Exp Immunol 1992, 89:46-51.
89. Eguchi K., Matsuoka N., Ida H., et al. Primary Sjogren's syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis 1992, 51:769-776.
90. Horiuchi M., Yamano S., Inoue H., et al. Possible involvement of IL-12 expression by Epstein-Barr virus in Sjogren syndrome. JClin Pathol 1999, 52:833-837.
91. Zheng L., Yu C., Zhang Z., et al. Expression of interferon regulatory factor 1, 3, and 7 in primary Sjogren syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 107:661-668.
92. Mavragani C.P., Crow M.K. Activation of the type I interferon pathway in primary Sjogren's syndrome. JAutoimmun 2010, 35:225-231.
93. Pascual V., Chaussabel D., Banchereau J. Agenomic approach to human autoimmune diseases. Annu Rev Immunol 2010, 28:535-571.
94. Guilherme L., Ferreira F.M., Kohler K.F., et al. Avaccine against Streptococcus pyogenes: the potential to prevent rheumatic fever and rheumatic heart disease. Am J Cardiovasc Drugs 2013, 13:1-4.